您当前所在的位置:首页 > 产品中心 > 产品信息
Dalfopristin_分子结构_CAS_112362-50-2)
点击图片或这里关闭

Dalfopristin

产品号 DB01764 公司名称 DrugBank
CAS号 112362-50-2 公司网站 http://www.ualberta.ca/
分子式 C34H50N4O9S 电 话 (780) 492-3111
分子量 690.8472 传 真
纯 度 电子邮件 david.wishart@ualberta.ca
保 存 Chembase数据库ID: 1537

产品价格信息

请登录

产品别名

标题
Dalfopristin
IUPAC标准名
(6R,10R,11R,12Z,17Z,19Z,21S)-6-[2-(diethylamino)ethanesulfonyl]-21-hydroxy-11,19-dimethyl-10-(propan-2-yl)-9,26-dioxa-3,15,28-triazatricyclo[23.2.1.0^{3,7}]octacosa-1(27),12,17,19,25(28)-pentaene-2,8,14,23-tetrone
IUPAC传统名
(6R,10R,11R,12Z,17Z,19Z,21S)-6-[2-(diethylamino)ethanesulfonyl]-21-hydroxy-10-isopropyl-11,19-dimethyl-9,26-dioxa-3,15,28-triazatricyclo[23.2.1.0^{3,7}]octacosa-1(27),12,17,19,25(28)-pentaene-2,8,14,23-tetrone
别名
Dalfopristine [inn-french]
Dalfopristina [inn-spanish]
Dalfopristinum [inn-latin]

产品登记号

PubChem SID 46506561
PubChem CID 21943991
CAS号 112362-50-2

产品性质

产品详细信息

详细说明 (English)
Item Information
Drug Groups approved
Description Dalfopristin is a combination of two antibiotics (Dalfopristin and quinupristin) used to treat infections by staphylococci and by vancomycin-resistant Enterococcus faecium. It is not effective against Enterococcus faecalis infections. Dalfopristin inhibits the early phase of protein synthesis in the bacterial ribosome and quinupristin inhibits the late phase of protein synthesis.
Indication For the treatment of bacterial infections (usually in combination with quinupristin).
Pharmacology Dalfopristin is a streptogramin antibiotic, derived from pristinamycin IIA.
Affected Organisms
Enteric bacteria and other eubacteria
Biotransformation Converted to an active non-conjugated metabolite by hydrolysis.
Half Life The elimination half-life is approximately 0.70 hours.
Protein Binding Moderate
References
Allington DR, Rivey MP: Quinupristin/dalfopristin: a therapeutic review. Clin Ther. 2001 Jan;23(1):24-44. [Pubmed]
Lamb HM, Figgitt DP, Faulds D: Quinupristin/dalfopristin: a review of its use in the management of serious gram-positive infections. Drugs. 1999 Dec;58(6):1061-97. [Pubmed]
Manzella JP: Quinupristin-dalfopristin: a new antibiotic for severe gram-positive infections. Am Fam Physician. 2001 Dec 1;64(11):1863-6. [Pubmed]
Paradisi F, Corti G, Messeri D: Antistaphylococcal (MSSA, MRSA, MSSE, MRSE) antibiotics. Med Clin North Am. 2001 Jan;85(1):1-17. [Pubmed]
External Links
Wikipedia

参考文献

  • Lamb HM, Figgitt DP, Faulds D: Quinupristin/dalfopristin: a review of its use in the management of serious gram-positive infections. Drugs. 1999 Dec;58(6):1061-97. Pubmed
  • Manzella JP: Quinupristin-dalfopristin: a new antibiotic for severe gram-positive infections. Am Fam Physician. 2001 Dec 1;64(11):1863-6. Pubmed
  • Paradisi F, Corti G, Messeri D: Antistaphylococcal (MSSA, MRSA, MSSE, MRSE) antibiotics. Med Clin North Am. 2001 Jan;85(1):1-17. Pubmed
  • Allington DR, Rivey MP: Quinupristin/dalfopristin: a therapeutic review. Clin Ther. 2001 Jan;23(1):24-44. Pubmed